Anavex Life Sciences (NASDAQ: AVXL) and Windtree Therapeutics (OTCMKTS:WINT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.
This is a breakdown of recent ratings and recommmendations for Anavex Life Sciences and Windtree Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anavex Life Sciences||0||0||2||0||3.00|
Anavex Life Sciences currently has a consensus target price of $14.50, indicating a potential upside of 351.71%. Given Anavex Life Sciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Windtree Therapeutics.
Earnings & Valuation
This table compares Anavex Life Sciences and Windtree Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Anavex Life Sciences||N/A||N/A||-$14.73 million||($0.33)||-9.73|
|Windtree Therapeutics||$2.04 million||7.44||-$39.49 million||($3.59)||-0.07|
Anavex Life Sciences has higher earnings, but lower revenue than Windtree Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Anavex Life Sciences and Windtree Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anavex Life Sciences||N/A||-70.10%||-63.39%|
Risk and Volatility
Anavex Life Sciences has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500.
Institutional and Insider Ownership
23.9% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 0.3% of Windtree Therapeutics shares are held by institutional investors. 11.6% of Anavex Life Sciences shares are held by company insiders. Comparatively, 0.8% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Anavex Life Sciences beats Windtree Therapeutics on 9 of the 12 factors compared between the two stocks.
About Anavex Life Sciences
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.
About Windtree Therapeutics
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial ugg australia sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.
Thank you for taking the time to read this article. I hope you like it